SEC Form 4 · accession 0001209191-18-023136
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Tarriff
Officer — CEO · Director
Period of report
Mar 30, 2018
Accepted (ET)
Apr 3, 2018 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 30, 2018 | M | 113,104 | $4.04 | A | 1,483,050 | D | |
| Common StockF1 | Mar 30, 2018 | F | 57,895 | $52.69 | D | 1,425,155 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $4.04 | Mar 30, 2018 | M | 113,104 | D | — | Oct 2, 2018 | Common Stock | 113,104 | 0 | D |
Explanation of responses
- F1Represents shares withheld to pay exercise price and to satisfy withholding tax obligations.
- F2Fully vested.